Leap Therapeutics Q3 net loss $13.7M; DKN-01 colorectal study expands to Part B

CYPHERPUNK TECHNOLOGIES INC.

2023-Q3 EPS reported -$3.78

Net loss $13.7M in Q3 2023 vs $15.1M in Q3 2022; cash and equivalents $80.7M.
DKN-01 DeFianCe Part A met >20% ORR threshold; Part B with 130 patients now enrolling; data at Jan 2024 med conf.
DisTinGuish gastric cancer Part C enrollment expected by end 2023; prior data showed 73% ORR, 19.5 mo OS.
R&D expenses $11.5M vs $12.1M; G&A $3.3M vs $3.2M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2023 results: net income Net Loss was $13.7 million.

Period: the third quarter ended September 30, 2023
Net income: Net Loss was $13.7 million
Result: reported results

Exact text from the filing

Net Loss was $13.7 million for the third quarter 2023, compared to $15.1 million for the same period in 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-116657

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.